A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

The FDA has granted Fast Track designation to PP-01 for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder.